JIR
HAE icon

James Investment Research’s Haemonetics HAE Stock Holding History

James Investment Research’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-589
Closed -$49K – 376
2023
Q1 		$49K Sell
589
-169
-22% -$13.7K 0.01% 365
2022
Q4 		$60K Sell
758
-1,135
-60% -$91.2K 0.01% 342
2022
Q3 		$140K Buy
+1,893
New +$136K 0.02% 289

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

James Investment Research's HAE Position: Q2 2023 in Review

James Investment Research sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 589 shares — an estimated $49K sold.

James Investment Research first reported a position in HAE in Q3 2022 and held it in 3 quarters. The position peaked at $140K in Q3 2022. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

  • James Investment Research reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
  • James Investment Research sold 589 Haemonetics shares in Q2 2023, an estimated $49K.
  • James Investment Research first reported a position in Haemonetics in Q3 2022 and held it in 3 quarters.
  • James Investment Research's Haemonetics position peaked at $140K in Q3 2022.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on James Investment Research's 13F filing for Q2 2023, filed 7 Aug 2023.